Evidence map›Paper›PMID 30073615›Full record

SynthesisInternational urology and nephrology2018

Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis.

Dengpiao Xie, Jianting Wang, Xinping Wu, Mingquan Li

Abstract readMeta-AnalysisReview
PubMed Publisher
In one paragraph

Synthesis in International urology and nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Dengpiao XieChengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Jianting WangPeople's Hospital of Fujian Province, Fuzhou, Fujian, China.
Xinping WuChengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Mingquan LiThe Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China. 3511725549@qq.com.
Chengdu University of Traditional Chinese Medicine · CNFujian Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe efficacy of daprodustat for the treatment of anemic patients with chronic kidney disease (CKD) remains controversial. The aim of the study is to perform a meta-analysis of randomized controlled trials to evaluate the efficacy and safety of daprodustat for anemic patients with chronic kidney disease.

methodsWe searched Medline, Embase, Science Citation Index, Cochrane Central Register of Controlled Trials, and Clinical Trial Registries for randomized controlled trials comparing daprodustat with placebo for anemic patients with CKD.

resultsFour studies were included. Compared with placebo groups, daprodustat groups significantly increased hemoglobin (WMD 1.29 g/dL; 95% CI 0.96-1.62, p < 0.00001), transferrin (WMD 0.67 g/dL; 95% CI 0.45-0.89, p < 0.00001), and total iron binding capacity (WMD 9.97 g/dL; 95% CI 6.07-13.8, p < 0.00001). Daprodustat groups significantly decreased hepcidin (WMD - 76.1 μg/L; 95% CI - 91.8 to - 60.3, p < 0.00001) and ferritin (WMD - 63.6 μg/L; 95% CI - 96.6 to - 30.7, p = 0.0002) compared with that of placebo groups. In addition, there was no significant difference in adverse events between the two groups.

conclusionDaprodustat could improve hemoglobin without increasing adverse events in the short term. Daprodustat may be another valuable choice for anemic patients with chronic kidney disease in the future.

Indexed as

AnemiaBarbituratesGlycineHemoglobinsHepcidinsHumansHypoxia-Inducible Factor-Proline DioxygenasesProlyl-Hydroxylase InhibitorsRandomized Controlled Trials as TopicRenal Insufficiency, ChronicTransferrinBarbituratesGlycineGSK1278863HemoglobinsHepcidinsHypoxia-Inducible Factor-Proline DioxygenasesProlyl-Hydroxylase InhibitorsTransferrinChronic kidney diseaseDaprodustatMeta-analysis

Identifiers

PMID30073615
OpenAlexW2887185662

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.